Syngene International Unveils State-of-the-Art Peptide Laboratory and Automation for Faster Drug Development

Syngene International Invests in Peptide Laboratory and Advanced Automation

Syngene International, a prominent player in the global contract research, development, and manufacturing segment, has recently announced significant enhancements to its operations aimed at accelerating the drug discovery process. These site upgrades, executed in Bengaluru and Hyderabad, are designed to help clients expedite the introduction of innovative therapies to the marketplace.

The heart of this initiative is a cutting-edge peptide laboratory situated in Bengaluru. This laboratory stands out as it is specifically tailored to produce a diverse array of molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates. Notably, the lab can scale up synthesis to 800 mmol, making it a highly adaptable facility for various research needs. By incorporating six automated peptide synthesizers, each equipped with robotic arms, Syngene can drastically cut down project timelines – potentially reducing them by weeks or even months – while ensuring the delivery of consistent results. The lab also features state-of-the-art techniques such as Solid-Phase Peptide Synthesis (SPPS) and High-Performance Liquid Chromatography (HPLC), coupled with comprehensive Quality Control measures to provide smooth transitions from research discovery to development.

Additionally, Syngene has embraced automation in its Drug Metabolism and Pharmacokinetics (DMPK) operations. This transformation entails the deployment of robotic systems for high-throughput sample preparation, yielding a remarkable reduction in turnaround times from five days to just three while enhancing cost efficiency by 30%. Moreover, the automation approach triples sample capacities, enabling clients to gain access to critical data much faster than ever before. The company’s Direct-to-Biology (D2B) platform is another noteworthy advancement. It accelerates the hit-to-lead process and lead optimization through rapid compound design, miniaturized synthesis, and high-throughput screening—this innovation can save a week for 24-compound sets and even more for larger sets.

Peter Bains, the Managing Director and CEO of Syngene, shared insights into the company’s strategic direction. He stated, “At Syngene, we are committed to integrating advanced automation technologies into our research and development workflows to speed up scientific discovery and enhance operational efficiency. These capabilities not only boost throughput and reproducibility but also free our teams to concentrate on high-value scientific challenges, thereby better supporting our customers.”

The establishment of the dedicated peptide laboratory marks a significant milestone for Syngene. It underscores the increasing importance of peptides in therapeutic development and equips the company to support partners across all stages—from synthesis and purification to characterization and early-stage development. Bains emphasized that through this integration of automation with scientific expertise, Syngene is building a robust platform that facilitates therapeutic innovation while delivering enhanced value to clients under one roof.

In line with these advancements, Syngene will be present at the CPHI Frankfurt event, where attendees can learn more about these investments and their implications for the pharmaceutical landscape.

About Syngene:
Syngene International Ltd. (BSE 539268) (NSE SYNGENE) is a comprehensive research, development, and manufacturing service provider catering to diverse sectors, including pharmaceuticals, biotechnology, and specialty chemicals. With a team comprising over 5,600 scientists, the company holds a reputation for delivering scientific excellence, robust data security, and top-tier manufacturing speed to improve time-to-market and reduce innovation costs. Syngene operates more than 2.5 million square feet of specialized facilities, collaborating with around 400 global customers, including biopharmaceutical innovators and major multinational corporations such as BMS, GSK, Zoetis, and Merck KGaA. For further details, visit Syngene's website.